Alopecia Treatment Market is accounted for USD 7,325.0 million in 2019 with 4.9% CAGR by 2026 | Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck & Co., Inc.

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Get Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables, and Figures) of Alopecia Treatment, https://www.coherentmarketinsights.com/insight/request-pdf/1847

Global Alopecia Treatment Market, by Disease Type (Androgenic Alopecia, Alopecia Areata, and Others), By Drug Type (Topical Agents, 5 AR Inhibitors, Corticosteroids, and Others), by Gender (Male and Female), By Route of Administration (Oral, Topical, and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 7,325.0 million in 2017, and is estimated to exhibit a CAGR of 4.9% over the forecast period (2018-2026).

Increasing regulatory product approvals and product launches by market players are expected to augment the market growth

Major market players are engaged on product launches and focusing on receiving product approvals from regulatory bodies, in order to develop novel products to address critical unmet needs of patients. For instance, in July 2018, Aclaris Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) grant as the Fast Track designation to Aclaris’ investigational topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502) for the treatment of alopecia areata, including patchy alopecia areata and variants of the disease, alopecia totalis and universalis. Moreover, robust pipeline is expected launch advanced drugs for alopecia in the near future, which is expected to boost the market growth over the forecast period. For instance, in June 2018, Almirall, a company based in Spain, published the results of Phase III trial of ALM12845/P-3074 for androgenic alopecia. The company is planning for the regulatory filing of the drug in the E.U. by the end of 2019.

Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1847

Furthermore, rising adoption of chemotherapy and radiation therapy for treatment of cancer, induces alopecia, which are expected to drive the global alopecia treatment market growth over the forecast period. For instance, according to the study published in National Center for Biotechnology Information (NCBI), February 2017, incidence of alopecia associated with chemotherapy drug categories such as topoisomerase inhibitors causes around 60% to 100% alopecia, Anti microtubule agents caused around 80% alopecia.

Additionally, key players in the market are focusing on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a company focused on discovery and development of kinase inhibitors to treat autoimmune disorders such as alopecia areata, vitiligo, atopic dermatitis, and others, in 2017.

Browse 31 Market Data Tables and 25 Figures spread through 193 Pages and in-depth TOC on ‘Alopecia Treatment Market’- Global Forecast to 2026, by Disease Type (Androgenic Alopecia, Alopecia Areata, and Others), By Drug Type (Topical Agents, 5 AR Inhibitors, Corticosteroids, and Others), by Gender (Male and Female), By Route of Administration (Oral, Topical, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the global alopecia treatment market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/alopecia-treatment-market-to-surpass-us-112-billion-by-2026-953

Key Takeaways of the Global Alopecia Treatment Market:

• The global alopecia treatment market is expected to exhibit a CAGR of 4.9% over the forecast period, attributed to increasing prevalence of alopecia. For instance, according to the Orphanet Report, in January 2019, the prevalence of Alopecia Universalis was around 25/100,000 and Alopecia Totalis was around 10.5/ 100,000 among population in Europe.
• Among disease type, androgenic alopecia segment held a dominant position in the global alopecia treatment market in 2018, attributed to increasing incidence of androgenic alopecia and rising number of ongoing clinical trials. For instance, in March 2019, Assiut University initiated clinical trial to study the role and efficacy of Vitamin D in treatment of androgenic alopecia. The study was expected to complete in December 2019.
• Among drug type, topical agents segment accounted for a major market share in the global alopecia treatment market in 2018, attributed to increasing number of drug candidates in the category of topical agents. For instance, in May 2018, Energenesis Biomedical Co., Ltd., collaborated with A2 Healthcare Taiwan Corporation to initiate phase 2 clinical trial to evaluate the efficacy and safety of ENERGI-F701 solution for topical use in female pattern baldness. The study was completed in March 2019.
• Major players operating in the global alopecia treatment market include Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck & Co., Inc., Daiichi Sankyo Company, Limited, and Sun Pharmaceutical Industries Ltd.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.